Debt-free Balance SheetZero reported debt materially reduces near-term solvency risk and interest obligations. For a small biotech, lack of leverage preserves strategic optionality to pursue trials, partnerships, or licensing without servicing debt, giving management time to execute over the next several months.

Narrowing Losses In Some YearsIntermittent narrowing of operating and net losses suggests management has taken cost-control or prioritization actions. If sustained, this trajectory can extend runway, improve operational discipline, and make the company a more viable partner or financing candidate over a 2–6 month horizon.

Lean Operating StructureA 15-person headcount implies a very lean cost base and operational flexibility. Structurally low fixed overhead can stretch available cash, enable focused R&D spending, and reduce near-term financing needs compared with larger peers, supporting survivability while seeking partnerships.

Bears Say

Persistent Negative Cash FlowConsistent annual negative operating and free cash flow, culminating in ~-¥1.39B in 2025, is a structural cash-burn problem. Over 2–6 months this necessitates external funding or asset monetization; failure to secure capital would constrain R&D and operational continuity.

Severe Revenue ContractionA ~95% revenue collapse from an already small base indicates weak commercial traction or a disrupted revenue stream. Structurally volatile and tiny revenue undermines scalability and makes achieving break-even materially harder without new products, partnerships, or durable revenue drivers.

Eroding Financial CushionDeclining equity and assets over multiple years reflect cumulative losses and shrinking financial resources. Even with no debt, a diminished balance sheet reduces ability to absorb setbacks, fund trials, or negotiate favorable collaborations, heightening funding and execution risk.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥75.00 and its highest was ¥143.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥4.54B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is May 18, 2026 which is in 69 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Feb 12, 2026. The company reported -¥17.06 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.06.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 40,563,800 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥17.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.97%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.